Terns Pharmaceuticals
TERN
TERN was delisted on the 4th of May, 2026.
37 hedge funds and large institutions have $117M invested in Terns Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 3 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
9% more funds holding
Funds holding: 34 → 37 (+3)
0.88% less ownership
Funds ownership: 66.55% → 65.67% (-0.88%)
33% less capital invested
Capital invested by funds: $174M → $117M (-$57.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Antara Capital
New York
|
+$1.46M |
| 2 |
BlackRock
New York
|
+$1.19M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$980K |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$942K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$795K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MICM
Matthews International Capital Management
San Francisco,
California
|
-$9.12M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.1M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$269K |
| 4 |
STB
S&T Bank
Indiana,
Pennsylvania
|
-$104K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$103K |
TERN Hedge Fund Activity: Q4 2021 in Review
37 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q4 2021, worth a combined $117M — down 33% from $174M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TERN positions and 3 closed out — a net gain of 3 holders — while 16 added to existing stakes and 6 trimmed.
The largest buyer was Antara Capital, adding an estimated $1.46M. The largest seller was Matthews International Capital Management, exiting entirely with an estimated $9.12M sold.
- 37 institutional investors held Terns Pharmaceuticals (TERN) as of Q4 2021, up from 34 in Q3 2021.
- Funds reported $117M of Terns Pharmaceuticals stock for Q4 2021, down 33% quarter-over-quarter.
- 6 funds opened new Terns Pharmaceuticals positions in Q4 2021 and 3 closed out, a net change of +3 holders.
- The largest Terns Pharmaceuticals buyer in Q4 2021 was Antara Capital, an estimated $1.46M added.
- The largest Terns Pharmaceuticals seller in Q4 2021 was Matthews International Capital Management, an estimated $9.12M sold.
Based on aggregated 13F filings for Q4 2021.